Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych VivasAddiction psychiatry

Psych Vivas · Addiction psychiatry

Alcohol use disorder — structured clinical viva

Fellowship viva on delirium tremens, CIWA-Ar, thiamine/Caine, naltrexone opioid trap, acamprosate/disulfiram doses, dual diagnosis pointer.

clinical
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
You are the psychiatry registrar. A 47-year-old with severe alcohol dependence is day two after emergency admission. Last drink about 50 hours ago. He is sweaty, tachycardic, fluctuating orientation, describing insects on the bed. Nursing staff ask whether this is 'just behavioural' and whether antipsychotics first are enough. His partner wants naltrexone started tonight while he is still on PRN oxycodone for rib fractures. Defend diagnosis, differentials, emergency management with doses, Wernicke prevention, and longer-term pharmacotherapy/psychosocial plan.

Interpretation

Reveal interpretation

Diagnosis. Delirium tremens — ~50 hours after last drink, fluctuating consciousness, severe autonomic hyperactivity, formed hallucinations. This is a medical emergency, not a primary behavioural disturbance.[1]

Differential. Other delirium (infection, metabolic, head injury from trauma), Wernicke encephalopathy (may coexist), alcohol hallucinosis without full delirium, benzo withdrawal if co-dependent, hepatic encephalopathy if cirrhotic.[1][3][6]

Immediate management. Continuous monitoring; CIWA-Ar if usable but do not withhold treatment if unassessable; high-dose benzodiazepines titrated to control agitation/autonomics (agent choice: diazepam or lorazepam if liver disease — name local protocol); parenteral thiamine high-dose if Wernicke risk; electrolytes (Mg/K/phosphate); medical/ICU escalation if refractory. Antipsychotics are not first-line for DT physiology.[1][2][6]

Naltrexone tonight. No while on oxycodone — precipitated opioid withdrawal and blocked analgesia. After opioid-free interval and consent, oral naltrexone 50 mg daily (or XR-NTX later) is reasonable; alternatives acamprosate 666 mg TDS or supervised disulfiram. Pair with psychosocial care; cite COMBINE nuances if asked.[4][5]

Escalating viva probes

ProbeModel point
CIWA-Ar structureTen items, max 67; symptom-triggered benzos
Caine criteriaAny 2 of 4 → treat as Wernicke
Seizure windowRoughly 12–48 h after last drink
Acamprosate dose666 mg TDS; renal adjust
COMBINE pearlNaltrexone/medical management effects; acamprosate null in that design

Key points

DT is medical

Severe autonomic delirium after alcohol cessation needs benzos and ICU-capable care, not antipsychotics-first.

Thiamine early

Parenteral thiamine for Wernicke risk; Caine beats waiting for the triad.

Opioid-free before naltrexone

Do not start naltrexone on ongoing oxycodone.
[1] [3] [4]

References

  1. [1]Mayo-Smith MF Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. JAMA, 1997.PMID 9214531
  2. [2]Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict, 1989.PMID 2597811
  3. [3]Caine D, Halliday GM, Kril JJ, et al. Operational criteria for the classification of chronic alcoholics: identification of Wernicke's encephalopathy. J Neurol Neurosurg Psychiatry, 1997.PMID 9010400
  4. [4]Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. Am J Psychiatry, 2018.PMID 29301420
  5. [5]Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA, 2006.PMID 16670409
  6. [6]Galvin R, Bråthen G, Ivashynka A, et al. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. Eur J Neurol, 2010.PMID 20642790